Vexev and U.S. Renal Care announced the results of the CANSCAN feasibility trial, which provided evidence that Vexev’s V ...

Vexev and U.S. Renal Care today announced successful results from the CANSCAN trial of the VxWave robotic ultrasound imaging system.

Vexev, an Australian-based medical device company advancing next-generation vascular imaging, and U.S. Renal Care, a leading provider of in-center and home dialysis in the United States, announced the ...

For the first time, a team of Inserm researchers from the Physics for Medicine Institute (Inserm/ESPCI Paris-PSL/CNRS) has succeeded in mapping the blood flow of an entire organ in animals (heart, ...

Thank you, Philip Trip Taylor. At our core, Pulse Biosciences creates, markets, and services generated by our nPulse ...

Venous reflux disease (VRD) occurs when veins do not properly return blood to the heart. Health experts refer to it as chronic venous insufficiency (CVI). VRD most commonly affects the legs and can ...

HEPARIN has been proved an effective agent for the prevention of intravascular thrombosis in laboratory animals 1 and is more effective than bis-hydroxycoumarin in preventing thrombosis of stagnant, ...

Gadolinium chelates are commonly used to improve tissue contrast in MRI. Until recently the use of gadolinium was thought to be risk-free compared with alternative contrast agents. Recent studies, ...

Flabby arms aren’t a lost cause after 50, you just need the right approach. Tightening arm jiggle comes down to consistent training that tones your triceps, shoulders, and upper back without adding ...

Peripheral artery disease (PAD) is a common cardiovascular disease associated with increased risk of amputation, myocardial infarction, stroke, and death, as well as impaired quality of life (QOL), ...

Abstract: Skull-induced phase aberrations and signal attenuation limit the performance of transcranial ultrasound imaging, typically confining applications to the temporal region. While adaptive ...

Background: Hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) exhibit a dismal prognosis, occurring in 44%–62.2% of cases at initial diagnosis. The optimal treatment for ...